Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Apr 1.

Published in final edited form as: J Cancer Surviv. 2020 Jan 13;14(2):226–234. doi: 10.1007/s11764-019-00815-4

Table 1:

Study 1 sample demographics at baseline

		PPI Users (n = 36)		Non-users (n = 173)

Measure		N (%)	M (SD)	N (%)	M (SD)
Age			59.6(12.8)^*		54.8(11.1)^*
Comorbidities			1.1(1.5)		0.7(1.3)
Months before cancer tx			0.5(0.5)		0.7(0.6)
Race (% White)		25(69%)		138(80%)
Education	High School	16(44%)		44(26%)
	Some College	6(17%)		37(22%)
	College Grad	6(17%)		44(26%)
	Grad Training	8(22%)		47(27%)
Chemo tx (% Yes)		13(36%)		77(45%)
Radiation tx (% Yes)		20(56%)		92(53%)
Hormone tx (% Yes)		22(60%)		122(71%)
CES-D score			17.3(10.1)		16.4(10.8)
Cancer Stage	Stage 0	5(14%)		34(20%)
	Stage I	20(56%)		72(42%)
	Stage II	9(25%)		46(27%)
	Stage III	2(6%)		19(11%)

^*

p<0.05